Browsing tag:

multiple myeloma


Carfilzomib shined in pharmaceutical headlines recently with encouraging study data being shared in June 2015. Known as the brand name anticancer therapy Kyprolis, which is marketed by Onyx, the Carfilzomib injection proved to be superior to a Bortezomib-Dexamethasone combination treatment in patients with refractory multiple myeloma. Carfilzomib is an effectual single-agent therapy and proteasome inhibitor[…]

Read More

Impressive news dominated the headlines at the 56th American Society of Hematology annual meeting regarding anti-cancer powerhouse Pomalidomide. Results from a comprehensive study conducted by Celgene Corporation, the company that markets the brand name of Pomalidomide, POMALYST, were extremely encouraging. The trial, coined STRATUS, involved 599 patients suffering from refractory or relapsed multiple myeloma. Patients[…]

Read More

The National Institute for Health and Care Excellence {NICE} in the U.K. approved Bortezomib for multiple myeloma treatment on March 21, 2014. This serious, and often fatal blood cancer affects roughly 4500 patients in the U.K. each year. Multiple myeloma is projected to afflict about 24,000 new patients in the United States in 2014, with[…]

Read More

Thalidomide, known as the brand name Thalomid, is a known therapy for patients who are newly diagnosed with multiple myeloma. Patients who have been recently diagnosed with multiple myeloma are often given a combination treatment of Thalidomide and dexamethasone. Recently, research has shown that there are new possible uses for Thalidomide to treat a variety of[…]

Read More

Lenalidomide created quite a stir on Wall Street on July 11, 2013 when shares of Celgene’s Revlimid, the brand name of Lenalidomide, soared. The frenzy occurred after Celgene released data from the Phase 3 study of Lenalidomide, revealing  the great success of this blood cancer drug. Lenalidomide proved in Phase 3 studies to effectively halt[…]

Read More

February 8, 2013 – Pomalidomide Now Approved by the FDA to Treat Multiple Myeloma under the FDA’s accelerated approval program. Pomalidomide therapy was also granted orphan product designation as it is intended to treat a rare disease.  Marketed as Pomalyst by Celgene, Pomalidomide, CAS 19171-19-8, is a last chance treatment for patients with Multiple Myeloma[…]

Read More

The World Health Organization has predicted over 20 million new cancer cases in 2015 worldwide. This seemingly unbelievable number is not only astonishing; it is also a dire warning from the WHO. With the future onslaught of patients needing cancer care and treatments, the WHO has been urging researchers to continue to develop new products[…]

Read More

The Oncology segment of the pharmaceutical industry is not only a fast growing one, but it is also an area where shortages are anticipated. A decrease in availability of sterile injectable oncology drugs have been reported since 2007.  Furthermore, many of the sterile injectable oncology drugs that experienced shortages in 2010 and 2011 had a[…]

Read More

Denosumab, CAS number 615258-40-7, offers divergent options for researchers working with this monoclonal antibody. The scope of efficacy for denosumab is wide, with one of it’s uses being an approved treatment of osteoporosis in women, particularly those women who are post menopausal. Known as the brand Prolia®, which is marketed by Amgen, denosumab is effectively[…]

Read More

Carfilzomib, CAS number 868540-17-4, is a late-stage, selective next-generation proteasome inhibitor for patients with multiple myeloma. Developed by Onyx, carfilzomib has the ability to irreversibly bind to and inhibit the chymotrypsin-like activity of the 20S proteasome, which is an enzyme that degrades unwanted cellular proteins. The subsequent inhibition of the proteasome-mediated proteolysis creates  a build-up[…]

Read More